AI Engines For more Details: Perplexity Kagi Labs You
Menopausal Symptoms Relief: Tibolone is used to alleviate menopausal symptoms such as hot flashes, night sweats, vaginal dryness, and mood swings. It acts as an estrogenic, progestogenic, and androgenic agent, providing relief from these symptoms.
Prevention of Osteoporosis: Tibolone helps prevent bone loss and osteoporosis in postmenopausal women by exerting estrogen-like effects on bone density and metabolism. It can help reduce the risk of fractures associated with osteoporosis.
Improvement of Sexual Function: Tibolone may improve sexual function and libido in postmenopausal women by increasing vaginal lubrication and reducing discomfort during intercourse.
Cardiovascular Health: Tibolone has been shown to have neutral or beneficial effects on cardiovascular risk factors, such as lipid profiles and markers of inflammation, in postmenopausal women. However, its overall impact on cardiovascular health is still debated.
Endometrial Protection: Unlike estrogen-alone therapy, tibolone does not increase the risk of endometrial hyperplasia or cancer because of its progestogenic activity, which protects the endometrium.
Breast Health: Tibolone may have a neutral or slightly protective effect on breast tissue, reducing the risk of breast cancer compared to estrogen-alone therapy. However, its long-term effects on breast health require further investigation.
Liver Function: Tibolone is associated with a low risk of hepatotoxicity, but liver function should be monitored periodically during treatment, especially in women with pre-existing liver conditions.
Metabolic Effects: Tibolone may influence metabolic parameters such as insulin sensitivity and lipid metabolism. It may have variable effects on glucose tolerance and body weight in different individuals.
Mood and Cognition: Tibolone may have positive effects on mood, cognitive function, and quality of life in postmenopausal women. It may alleviate symptoms of depression and anxiety associated with menopause.
Thromboembolic Risk: Like other forms of hormone therapy, tibolone may increase the risk of thromboembolic events such as deep vein thrombosis (DVT) and pulmonary embolism, particularly in women with additional risk factors.
Uterine Bleeding: Irregular uterine bleeding or spotting may occur during the initial months of tibolone therapy, but it usually resolves with continued treatment.
Contraindications: Tibolone is contraindicated in women with a history of breast cancer, endometrial cancer, or thromboembolic disorders. It should be used with caution in women with liver dysfunction or cardiovascular risk factors.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.6 | 0.6 | |
| Acne | 0.6 | 0.3 | 1 |
| ADHD | 5.6 | 0.9 | 5.22 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.1 | 2.1 | 0.48 |
| Allergies | 6.8 | 3.8 | 0.79 |
| Allergy to milk products | 1.6 | 1.6 | 0 |
| Alopecia (Hair Loss) | 1.3 | 1.3 | |
| Alzheimer's disease | 6.9 | 6.1 | 0.13 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.1 | 0.6 | 4.17 |
| Ankylosing spondylitis | 3.5 | 1.5 | 1.33 |
| Anorexia Nervosa | 1.6 | 3 | -0.88 |
| Antiphospholipid syndrome (APS) | 1.2 | 1.2 | |
| Asthma | 5.4 | 2.4 | 1.25 |
| Atherosclerosis | 2 | 1.7 | 0.18 |
| Atrial fibrillation | 3.8 | 1.9 | 1 |
| Autism | 8.6 | 8.4 | 0.02 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.4 | 1.4 | |
| Bipolar Disorder | 2.1 | 1.7 | 0.24 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 1.1 | 0.3 | 2.67 |
| Cancer (General) | 0.9 | 2.7 | -2 |
| Carcinoma | 4.7 | 2.6 | 0.81 |
| Celiac Disease | 2 | 3.5 | -0.75 |
| Cerebral Palsy | 1.4 | 1.3 | 0.08 |
| Chronic Fatigue Syndrome | 4.9 | 5.5 | -0.12 |
| Chronic Kidney Disease | 4.3 | 1.7 | 1.53 |
| Chronic Lyme | 0.7 | 0.8 | -0.14 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.5 | 2 | -0.33 |
| Chronic Urticaria (Hives) | 1.6 | 0.4 | 3 |
| Coagulation / Micro clot triggering bacteria | 1.5 | 1.3 | 0.15 |
| Cognitive Function | 3.5 | 1.6 | 1.19 |
| Colorectal Cancer | 7.4 | 2.7 | 1.74 |
| Constipation | 1.7 | 1 | 0.7 |
| Coronary artery disease | 2.3 | 2.5 | -0.09 |
| COVID-19 | 10.1 | 11 | -0.09 |
| Crohn's Disease | 7.8 | 5.4 | 0.44 |
| Cushing's Syndrome (hypercortisolism) | 0.5 | -0.5 | |
| cystic fibrosis | 0.8 | 1.9 | -1.37 |
| d-lactic acidosis (one form of brain fog) | 0.2 | 0.2 | |
| deep vein thrombosis | 2.7 | 1.4 | 0.93 |
| Denture Wearers Oral Shifts | 1.4 | 1.4 | |
| Depression | 10.3 | 8.5 | 0.21 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 2 | 2.4 | -0.2 |
| Endometriosis | 3.1 | 2.2 | 0.41 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 3.2 | 1.5 | 1.13 |
| erectile dysfunction | 2.2 | 0.3 | 6.33 |
| Fibromyalgia | 3.2 | 1.9 | 0.68 |
| Functional constipation / chronic idiopathic constipation | 5.4 | 3.4 | 0.59 |
| gallstone disease (gsd) | 3.4 | 1.2 | 1.83 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.4 | 1 | 0.4 |
| Generalized anxiety disorder | 2.7 | 2.6 | 0.04 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.4 | 1.1 | 1.18 |
| Graves' disease | 1.9 | 3.3 | -0.74 |
| Gulf War Syndrome | 0.9 | 1.3 | -0.44 |
| Halitosis | 1.5 | 0.3 | 4 |
| Hashimoto's thyroiditis | 3.1 | 0.9 | 2.44 |
| Heart Failure | 4.6 | 1.6 | 1.87 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 1.4 | 0.6 | 1.33 |
| hypercholesterolemia (High Cholesterol) | 0.7 | 0.1 | 6 |
| hyperglycemia | 2.2 | 1.2 | 0.83 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 0.3 | 1 |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 3.8 | 5.9 | -0.55 |
| Hypothyroidism | 0 | 1 | 0 |
| Hypoxia | 3.1 | 0.3 | 9.33 |
| IgA nephropathy (IgAN) | 1.9 | 4.9 | -1.58 |
| Inflammatory Bowel Disease | 8.9 | 7.2 | 0.24 |
| Insomnia | 2.3 | 2.5 | -0.09 |
| Intelligence | 1.7 | 1.7 | |
| Intracranial aneurysms | 1.4 | 0.9 | 0.56 |
| Irritable Bowel Syndrome | 7 | 5.1 | 0.37 |
| ischemic stroke | 2.9 | 1.7 | 0.71 |
| Liver Cirrhosis | 7.4 | 4.2 | 0.76 |
| Long COVID | 6.7 | 7.7 | -0.15 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1.2 | 1.1 | 0.09 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.2 | 0.9 | 0.33 |
| ME/CFS with IBS | 0.5 | 2.1 | -3.2 |
| ME/CFS without IBS | 1.7 | 2.1 | -0.24 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 2.1 | 0.6 | 2.5 |
| Metabolic Syndrome | 6.9 | 7.7 | -0.12 |
| Mood Disorders | 10.5 | 6.8 | 0.54 |
| multiple chemical sensitivity [MCS] | 0.7 | 0.1 | 6 |
| Multiple Sclerosis | 5.9 | 5.5 | 0.07 |
| Multiple system atrophy (MSA) | 0.7 | 0.7 | 0 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 3.1 | -9.33 |
| Neuropathy (all types) | 0.7 | 2.5 | -2.57 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.8 | 0.8 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5.4 | 4.5 | 0.2 |
| NonCeliac Gluten Sensitivity | 1.3 | 0.6 | 1.17 |
| Obesity | 9.7 | 7.7 | 0.26 |
| obsessive-compulsive disorder | 5.4 | 2.8 | 0.93 |
| Osteoarthritis | 3 | 1.2 | 1.5 |
| Osteoporosis | 3.2 | 1.6 | 1 |
| pancreatic cancer | 2.1 | 0.6 | 2.5 |
| Parkinson's Disease | 6.7 | 6 | 0.12 |
| Polycystic ovary syndrome | 5.6 | 2.4 | 1.33 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.8 | -0.5 |
| Primary sclerosing cholangitis | 2.5 | 2.4 | 0.04 |
| Psoriasis | 3.1 | 2.2 | 0.41 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 7 | 4.1 | 0.71 |
| Rosacea | 0.6 | 1 | -0.67 |
| Schizophrenia | 7.7 | 3.1 | 1.48 |
| scoliosis | 0.5 | 1 | -1 |
| Sjögren syndrome | 2.7 | 3.3 | -0.22 |
| Sleep Apnea | 2.2 | 1.8 | 0.22 |
| Slow gastric motility / Gastroparesis | 1.1 | 0.3 | 2.67 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.8 | 0.6 | 2 |
| Stress / posttraumatic stress disorder | 2.8 | 2.8 | 0 |
| Systemic Lupus Erythematosus | 4 | 1.9 | 1.11 |
| Tic Disorder | 1.1 | 1.2 | -0.09 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 4.5 | 4 | 0.13 |
| Type 2 Diabetes | 7.5 | 7.3 | 0.03 |
| Ulcerative colitis | 6.1 | 6.5 | -0.07 |
| Unhealthy Ageing | 4.2 | 2.2 | 0.91 |
| Vitiligo | 2.2 | 1.4 | 0.57 |
